RecommendationsRituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitidesRituximab : recommandations du Groupe français d’étude des vascularites (GFEV) pour son utilisation en traitement d’induction et d’entretien des vascularites nécrosantes associées aux ANCA de l’adulte
Section snippets
References (51)
Comment traiter une vascularite nécrosante ?
Presse Med
(2012)- et al.
Rituximab for ANCA-associated vasculitides: the French experience
Press Med
(2013) - et al.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open-label, phase 3 trial
Lancet
(2010) - et al.
Randomised trial of intravenous immunoglobulin as prophylaxis against infection in multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma
Lancet
(1994) - et al.
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. A prospective study in 117 patients
Presse Med
(2013) - et al.
Randomized clinical trial of extended versus standard azathioprine maintenance therapy in newly diagnosed positive PR3-ANCA vasculitis patients at high-risk for disease relapse
Presse Med
(2013) - et al.
The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting
J Clin Virol
(2008) - et al.
Management of the risk of hepatitis B virus reactivation in patients receiving immunosuppressive and immunomodulatory agents in internal medicine: data from the REACTI-B survey and proposal for a management algorithm
Rev Med Interne
(2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection
J Hepatol
(2012)- et al.
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease
Blood
(2010)
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS–Malignancies Consortium Trial 010
Blood
(2005)
Vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
Autoimmune Review
(2011)
Rituximab versus cyclophosphamide for ANCA-associated vasculitis
N Engl J Med
(2010)
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
N Engl J Med
(2010)
Rituximab for induction and maintenance treatment of ANCA-associated vasculitides. A multicenter retrospective study on 80 patients
Rheumatology (Oxford)
(2013)
2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides
Arthritis Rheum
(2013)
Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy
Ann Intern Med
(1993)
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations
Ann Rheum Dis
(2012)
The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort
Medicine (Baltimore)
(2011)
Churg–Strauss syndrome treated successfully with rituximab
Rheumatol Int
(2011)
Rituximab for the treatment of Churg–Strauss syndrome with renal involvement
Nephrol Dial Transplant
(2011)
Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement
Ann Rheum Dis
(2010)
Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement
Clin Exp Rheumatol
(2008)
Rituximab is effective in the treatment of refractory Churg–Strauss syndrome and is associated with diminished T-cell interleukin-5 production
Rheumatology (Oxford)
(2008)
Cited by (66)
ANCA associated vasculitis
2020, European Journal of Internal MedicineCitation Excerpt :HIV, HCV and HBV serology should be requested prior to its use. RTX may be used in HIV patients with CD4>50 [83,84] and with HCV infection [79]. In HBsAg and/or anti-HBc positive patients, prior or concurrently with RTX, entecavir/tenofovir must be initiated.
Therapeutic plasma exchange – A brief review of indications, urgency, schedule, and technical aspects
2019, Transfusion and Apheresis ScienceTargeted immunotherapy strategies in ANCA-associated vasculitis
2019, Joint Bone SpineTreatment of ANCA-associated vasculitides: Certainties and controversies
2019, Nephrologie et Therapeutique
- 1
French Vasculitis Study Group (www.vascularites.org).
Copyright © 2013 Published by Elsevier Masson SAS